


FROZEN GRAHAM CRACKER MINT SANDWICHES



Looking for a simple and cool treat for that sweet tooth?

Try these frozen graham cracker mint sandwiches. You may want to double the recipe, as once you share with a friend, they may disappear quickly! Serving size: 4

Ingredients

- 8 graham crackers, 4-inch squares
- 8 tablespoons low-sugar, fat-free, lactose-free whipped cream
- Small casserole dish
- 1 teaspoon nonalcoholic mint flavoring or other flavors, such as nonalcoholic vanilla, can be substituted

Steps

1. Place whipped cream in small bowl and mix with mint flavoring or flavoring of choice
2. Place 2 tablespoons of the flavored whipped cream on graham cracker square and top with another graham cracker square
3. Place in casserole dish
4. Place dish in freezer until frozen
5. Serve when ready. Store in freezer



For more recipes, tips, and helpful resources, like us on Facebook.com /SandostatinLARDepot

This recipe was created by our RealSupport™ nutritionist especially for our members. Remember, please talk to your health care provider to determine if this recipe or any other food is appropriate for you.

Please note that Novartis Pharmaceuticals Corporation does not endorse the use of any foods highlighted in this article; all information is provided for educational purposes only. Use of any food in this recipe is not intended to treat or cure carcinoid syndrome. You are advised to speak to your health care provider before introducing new foods into your diet.

Please see Important Safety Information on page 2.

Please [click here](#) for full Prescribing Information.

Brought to you by RealSupport™, a patient information and support program for those with the severe diarrhea and flushing of carcinoid syndrome. RealSupport™ is provided by Novartis Pharmaceuticals Corporation, the maker of Sandostatin® LAR Depot (octreotide acetate) for injectable suspension. For more information about the RealSupport™ program offerings, please follow us on www.facebook.com/SandostatinLARDepot.

INDICATIONS AND USAGE

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for

- Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
- Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors

In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

Before Taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Common Side Effects: Most patients experience side effects at some time. Some common side effects you may experience include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

Other Information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Please [click here](#) for full Prescribing Information.

To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit www.sandostatin.com.



Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

© 2019 Novartis

5/19

SDS-1214272

